• 1
    Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al.Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.Ann Rheum Dis2010;69:63843.
  • 2
    Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, Burmester G, et al.Treating rheumatoid arthritis to target: recommendations of an international task force.Ann Rheum Dis2010;69:6317.
  • 3
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.Ann Rheum Dis2010;69:96475.
  • 4
    Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, et al.Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry.Arthritis Care Res (Hoboken)2011;63:85664.
  • 5
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al, on behalf of All Departments of Rheumatology in Denmark.Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.Arthritis Rheum2010;62:2232.
  • 6
    Van Riel PL, van Gestel AM, van de Putte LB.Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers.Br J Rheumatol1996;35 Suppl:47.
  • 7
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL.Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria.Arthritis Rheum1996;39:3440.
  • 8
    Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al.Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic treatment has failed.Ann Rheum Dis2004;63:50816.
  • 9
    Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ.Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naïve, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.Ann Rheum Dis2011;70:211925.
  • 10
    Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K.RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.Arthritis Care Res (Hoboken)2011;63:11429.
  • 11
    Raspe HH, Hagedorn U, Kohlmann T, Mattussek S. Der Funktionsfragebogen Hannover (FFbH): ein instrument zur funktionsdiagnostik bei polyartikulären gelenkerkrankungen. In: Siegrist J, editor.Wohnortnahe betreuung rheumakranker: ergebnisse sozialwissenschaftlicher evaluation eines modellversuches.Stuttgart (Germany):Schattauer;1990. p.16482.
  • 12
    Uhlig T, Kvien TK, Pincus T.Test–retest reliability of disease activity core set measures and indices in rheumatoid arthritis.Ann Rheum Dis2009;68:9725.
  • 13
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis Rheum1995;38:448.
  • 14
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al.DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.Arthritis Res Ther2005;7:R106371.
  • 15
    Lautenschlager J, Mau W, Kohlmann T, Raspe HH, Struve F, Bruckle W, et al.Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire.Z Rheumatol1997;56:14455. In German.
  • 16
    Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C, et al.Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study.Rheumatol Int2012;32:275967.
  • 17
    Mowinckel P, Hagen KB, Heiberg T, Kvien TK.Repeated measures in rheumatoid arthritis reduced the required sample size in a two-armed clinical trial.J Clin Epidemiol2008;61:9404.
  • 18
    Lienert GA, Raatz U.Test construction and test analysis.Weinheim (Germany):Beltz/Psychologie Verlagsunion;1998. In German.
  • 19
    Winer BJ, Brown DR, Michels KM.Statistical principles in experimental design. 3rd ed.New York:McGraw-Hill;1991.
  • 20
    Weyer G, Eul A, Milde K, Wierich W, Herrmann WM.Cycandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.Pharmacopsychiatry2000;33:8997.
  • 21
    Fransen J, van Riel PL.The Disease Activity Score and the EULAR response criteria.Clin Exp Rheumatol2005;23 Suppl:S939.